Regeneron Pharmaceuticals, Inc. Live Stock Price Today, Share Analysis and Chart

Name: Regeneron Pharmaceuticals, Inc.: Is Infosys Ltd. worth buying?
Item: Regeneron Pharmaceuticals, Inc.
Rating: 2.221194375
Author: Trendlyne DVM scores

Mid-range Performer

about

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

568.20 12.37 (2.23%)

51.46% Fall from 52W High

868.1K

XNAS Volume

XNAS 11 Sep, 2025 5:30 PM (EDT)

Medium Financial Strength

44.4 / 100

Mid Valuation

44.2 / 100

Technically Neutral

44.6 / 100

Mid-range Performer These stocks average quality, financial and technical aspects make them being considered by the investor who are not looking for high risk stocks. View Similar Embed DVM

717

1Yr Price target upside is 26%

24 analysts

Regeneron Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Regeneron Pharmaceuticals, Inc. Live Stock Price Today, Share Analysis and Chart

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

51.46% Fall from 52W High

SWOT Analysis

Regeneron Pharma Live Price Chart